Advarra Acquires IRBco

April 21, 2020

Applied Clinical Trials

Advarra, the provider of institutional review board (IRB), institutional biosafety committee (IBC), research technology solutions, and quality and compliance consulting services is pleased to announce the acquisition of IRB Company, Inc. (IRBco), an AAHRPP-accredited central IRB that has conducted research reviews in the U.S. since 1981. Advarra continues to expand its presence as the largest provider of integrated IRB services in North America.

“Advarra builds on its commitment to advance human health and better enable clinical trials with this acquisition,” said Gadi Saarony, CEO of Advarra. “IRBco studies will be fully integrated with Advarra in a matter of weeks, and we look forward to the additional talent and board expertise this will bring to our organization. We will maintain our focus on developing altogether better capabilities that serve clients and protect research participants.”

Advarra offers a suite of products and services that simplify processes, create efficiencies, and support research compliance. These capabilities align to provide the research community and the biopharmaceutical industry with integrated solutions to advance healthcare in more meaningful ways. Plus, Advarra continues to extend the greatest institutional reach of any independent IRB, serving well over 3,200 research institutions, hospital systems, and academic medical centers.

“Joining the Advarra family is an ideal fit,” said Dr. Anil Sharma, CEO of IRBco. “We are pleased to offer our mutual customers expanded resources-innovations, efficiencies, and all the characteristics to collaboratively complement moving research forward.”